Lonial, S., Richardson, P., Cole, C., Farooq, A., Berkenstock, M., Byrne, J., Roy-Ghanta, S., Rogers, R., Phillips-Jones, A., McKeown, A., Afshari, N. (2025). Belantamab mafodotin (belamaf) ocular events are manageable and reversible with dose modifications guided by standard assessments. Blood. https://doi.org/10.1182/blood-2025-4055